Highlights KALA BIO, Inc.

Equities

KALA

US4831192020

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-09 pm EDT			5-day change	1st Jan Change
6.713 ^USD	-5.19%		-0.62%	-4.10%

Apr. 02	HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating	MT
Mar. 29	KALA BIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

KALA BIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
KALA BIO, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 29	CI
North American Morning Briefing : Stocks Struggle After New Records	Mar. 22	DJ
North American Morning Briefing : Inflation -2-	Mar. 15	DJ
KALA BIO, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
KALA BIO, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-04	CI
Kala Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Kala Pharmaceuticals, Inc. Announces Positive Safety Update from Cohort 1 of Chase Phase 2B Clinical Trial Evaluating KPI-012 in Patients with PCED	23-03-27	CI
KALA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	23-03-03	AQ
Kala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-03	CI
Kala Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-03	CI
Kala Pharmaceuticals Receives FDA Nod for Phase 2 Testing of Cornea Treatment, Triggering $25 Million in New Funding	22-12-27	MT
Kala Pharmaceuticals, Inc. Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED	22-12-27	CI
Hopes of China Easing COVID-19 Policy Lift Exchange-Traded Funds, US Stock Futures Premarket Tuesday	22-11-29	MT
Kala Pharmaceuticals Submits Investigational Drug Application for Corneal Defect Drug Candidate	22-11-29	MT
Kala Pharmaceuticals Launches $31 Million Private Placement	22-11-28	MT
KALA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-11-08	AQ
Kala Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-08	CI
KALA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-08-11	AQ
Kala Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights KALA BIO, Inc.

Equities

KALA

US4831192020

Highlights

Filters